A Lean, World-Class Team
Built from leading academic and biopharma institutions, the BioMimetix team brings experience spanning clinical development, regulatory strategy, translational science, and commercialization.
Greg Kunst
Executive Chairman
CEO of Valitor and Special Envoy & Senior Advisor to the Permanent Observer Mission to the United Nations for Water and Sanitation in Africa. Board member at CynosBio, Feliqs, SIME Diagnostics, and Pr3vent. Former CEO of Aurion Biotech. Raised over $250M in venture capital funding.
James Crapo
MD | Founder | CEO
Prior Chair of Medicine at National Jewish Health, inventor on key patents, leader of COPDGene and BioMimetix.
David Silberstein
PhD | COO / VP R&D
Pharma leadership in genomics, global launch of Symbicort/Pulmicort.
David MacLeod
PhD | CSO
Computational biology, biochemistry of brain diseases, radiation therapy physics, clinical trial design.
Sara Penchev
VP of Clinical Operations
Clinical trial design, regulatory filings, creation and support of investigative clinical networks.
Robert Hellewell
JD | CBO
Business strategies, legal and regulatory matters, contracts, antitrust & trade regulation.
Robert Ogden
CFO
Controller, financial reporting to tax and regulatory authorities, budget planning for public and private companies.
Shayne Gad
PhD | DABT | VP Safety & Regulatory
Scholarly publications on toxicology, numerous successful regulatory filings including IND, NDA, BDA, ANDA, and 510K.
John Wetzel
PhD | Director of CMC & Manufacturing
Drug design, GMP methods, contributed to development of two FDA-approved drugs. Expertise from Synaptic, Lundbeck, and Wetzel Consulting.